


# creos™ xeniform: an all-cancellous bone graft

## Natural surface topography


Low-temperature processing technique allows natural surface topography, the same as human bone, stimulating osteoblast bone regeneration.



**Multiporosity**  
Natural surface topography, the same as human bone

## Multiporous structure

Relatively large pore size (300–400 μm) compared to Geistlich Bio-Oss® (100–200 μm), which is favorable for blood vessel access and development.<sup>1,2</sup>



**x100 SEM**  
Larger pore size compared to Bio-Oss®

## Enhance bone regeneration and formation

Contains octacalcium phosphate crystal to enhance bone regeneration and formation.<sup>3\*</sup>



**x50,000 SEM**  
Octacalcium phosphate crystal embedded on the surface

## Long-term success in clinical setting

In the last 10+ years, creos xeniform has been used by leading dental surgeons around the world in multiple clinical indications.




**Long term results**  
Stable peri-implant bone level 11 years after tooth extraction and immediate implant placement with bone augmentation (position FDI 26)

Image courtesy of Dr. Lee, Myung Ho, Republic of Korea

## High percentage of newly regenerated bone


- In a study with 10 patients who underwent maxillary sinus graft with creos xeniform, the histomorphometric analysis showed a higher fraction of newly regenerated bone (23.5±0.1%) compared to residual graft materials (15.4±0.06%), 6-8 months post-surgery.<sup>1</sup>
- In an in-vivo model to evaluate the bone healing effect of biomaterials, the percentage of the newly formed bone with creos xeniform and Geistlich Bio-Oss® were comparable. No infections or complications observed after surgery.<sup>4</sup>



No statistically significant difference between groups at either time point.

\* as shown in animal model

## Clinical case



Images courtesy of Dr. Lanka Mahesh, India

A 28-year-old male patient reported with long-standing edentulous space in the central incisor (FDI position 21) replaced by a splinted crown and bone loss up to one-third of the apical portion in 22. Pre-operative clinical assessment (a) and CBCT (b,c) show the extent of the bone defect. NobelActive® implants are inserted (d,e) after the extraction and the cover screws are placed (f); the defect is subsequently filled with creos xenof orm and covered with Titanium-Reinforced Cytoplast™ membrane. Post-operative x-ray (g) and 5-month follow-up CBCT (h) show an evident horizontal and vertical bone volume gain. The integration of creos xenof orm is well visible at the 5-month re-entry (i) and in the 1-year follow-up x-ray (j). The clinical assessment at the 1-year follow-up reveals a stable situation (k).



Dr. Luigi Canullo  
Italy

**“Due to high hydrophilicity of creos xenof orm, the hydrated bone chips with blood or saline are homogeneous and easy to shape. This helps to obtain the desired bone volume and stability while supporting the environment for osteogenesis.”**



Dr. Liliana Silva  
Portugal

**“creos xenof orm is easy to handle and adapt in bone defects, and its fast wettability in saline or biological products is highly useful in guided bone regeneration procedures.”**



Dr. Lanka Mahesh  
India

**“I have used creos xenof orm over the last 7 years in various clinical indications, ranging from sinus lift to GBR and socket grafting. I am extremely pleased with the results clinically as well as histologically. I would highly recommend this product to the practicing clinicians.”**

## More to explore



Nobel Biocare  
Regeneratives



Lateral sinus  
augmentation  
Using creos xenof orm



Meet the  
regeneration  
experts on FOR

1. Lee JH, et al. Implant Dent. 2015;24(3):275-80 • 2. Anil A, et al. J Int Soc Prev Community Dent. 2020 28;10(5):634-42 • 3. Suzuki O, et al. Dent Mater J. 2020 31;39(2):187-199 • 4. Jung Y, et al. Materials (Basel). 2020 1;13(19):4391.

GMT 83844 GB 2305 © Nobel Biocare Services AG, 2023. All rights reserved. Distributed by: Nobel Biocare. Disclaimer: Nobel Biocare, the Nobel Biocare logotype and all other trademarks are, if nothing else is stated or is evident from the context in a certain case trademarks of Nobel Biocare. Please refer to nobelbiocare.com/trademarks for more information. Product images are not necessarily to scale. All product images are for illustration purposes only and may not be an exact representation of the product. Some products may not be regulatory cleared/released for sale in all markets. Please contact the local Nobel Biocare sales office for current product assortment and availability. Caution: Federal (United States) law or the law in your jurisdiction may restrict this device to sale by or on the order of a licensed clinician, medical professional or physician. See Instructions For Use for full prescribing information, including indications, contraindications, warnings and precautions. Ti-oss® (Chiyewon Co., Ltd.) is distributed as creos™ xenof orm since January 2023. Legal Manufacturer: Chiyewon Co., Ltd. 6F, 192 Gyeongchunro, Guri si, Gyeonggido, Korea 11927.

